



PRESS RELEASE

For immediate release, Seinäjoki, Finland, June 2nd, 2020

EEVIA HEALTH OY RECEIVES LARGE PURCHASE ORDERS FOR BERRY EXTRACT

Eevia Health Oy, a Finnish producer of organically-certified plant extracts, has received large purchase orders from US customers for elderberry extract, which is very popular as an immune-stimulant.

Eevia Health Oy has received significant orders for its new product **Feno-Sambucus 14**, which is an extract from elderberry. Only one single order from Barrington Nutritionals alone has a value of 820 000 euros. However, the overall order-potential for elderberry extracts is currently over 2 million euros. The challenge right now is to acquire enough raw materials to serve all orders, so Eevia Health Oy cannot confirm the total order demand.

"We have focused on the arctic bilberries and typical species in the arctic and have overlooked the large and robust market for elderberries. However, the same bio-active, the anthocyanins, we extract from elderberries, as we do from bilberries. It is, therefore, easy for us to manufacture Elderberry extracts. We have demand for elderberry extracts for several million euros. We have only accepted some of these orders due to working capital limitations and raw material challenges. The elderberry extracts will be a suitable extension to our polyphenol extracts from lingonberry, bilberry, and other berries," reveals Eevia Health Oy's sales manager Anna-Maija Vanhatalo.

Pickers harvest Elderberries (Sambucus) from a genus of flowering plants in the family Adoxaceae. Elderberry extracts are traditionally used as an immune stimulant, including against flu and colds and other her conditions.

ABOUT EEVIA HEALTH OY

Eevia Health Oy, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant material from the pristine Finnish forests above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands. The focus is on ingredients that protect human health prophylactically, meaning they work to reduce the risk of developing a disease. In its portfolio, Eevia Health has immune-modulating products that have effects on Th1-type cytokines, such as IFN- γ and TNF- α cell signaling molecules, which are very important in the immune response to pathogens (virus, bacteria). Similarly, Eevia Health is developing a new product that prevents protein accumulation in the RPE-cells in the Retina, which may reduce the risk of developing eye disease AMD (Age-Related Macular Degeneration).

Eevia Health is a small, but fast-growing Finnish manufacturer of 100% organically certified plant extracts. All raw materials, such as lingonberry, bilberry, Chaga-mushroom, and pine bark, are grown in the wild and hand-picked in a sustainable fashion. The safe and effective ingredients of high quality, such as high concentrate bilberry anthocyanin extracts (36%) and pine bark extracts, are sold globally as ingredients to dietary supplement and food applications. Eevia Health operates a modern green-chemistry production facility in Finland, located close to the raw material forest source in Finnish Lapland. The short value-chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.

For additional information, please contact:

Stein Ulve, CEO
Eevia Health Oy
Mobile: +358 400 22 5967
Email: stein.ulve@eeviahealth.com

Fred Ramberg, Chairman of the Board
Eevia Health Oy
Mobile: +358 500 46 0944
Email: rambergfred@gmail.com